Diabetes

The microbiome and inflammatory signature differs in patients with type 1 diabetes.

Diabetes-related outcomes significantly differ by state and insurance type.

Early-onset schizophrenia may predict a diabetes diagnosis.

Top news of the day from across the health care landscape.

Novel device can determine if a patient has pre-, type 1, or type 2 diabetes.

Increasing expression of hedgehog proteins may lead to speedier healing in patients with diabetes.

The prevalence of diabetes is 17% higher in rural areas than in urban areas.

A recent study indicates that continuous medication monitoring (CoMM) could serve as a valuable tool for community pharmacists, shifting the focus from dispensing to improving patient outcomes and medication use.

As outcomes-based contracting becomes more important, companies are aligning to promote the payment model.

Researchers in England set out to determine whether the risk of diabetes development was present at the onset of schizophrenia, as opposed to after a period of time with the illness.

The diabetic effects on surgical outcomes found to be overstated.

Individuals enrolled in high-deductible health plans face thousands in out of pocket costs.

Individuals with chronic diseases and high-deductible health insurance spend more than 10% on out-of-pocket costs.

Suliqua receives marketing authorization in the EU shortly after the product was approved in the United States as Soliqua.

Semaglutide was not shown to increase cardiovascular risks for patients with diabetes.

Metformin plus syrosingopine seen to shrink tumors in mice models of liver cancer.

Top news of the day from across the healthcare landscape.

Continuous glucose monitors (CGMs) may soon be eligible for coverage by the US Centers for Medicare and Medicaid Services (CMS).

Top news of the day form across the health care landscape

Philadelphia's

Drug combination more effective on cancer cell proliferation.

Diabetes screening tests may be inaccurate, and can lead to over and under treatment.

Officials noted a 54% decline in kidney failure in this population between 1996 and 2013, more than any racial and ethnic group.

Novo Nordisk and Glooko will create a digital health solution for diabetes management.